Jiangsu Hengrui Pharmaceuticals (01276): SHR-1049 Injection Receives Drug Clinical Trial Approval Notification

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, the company received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-1049 injection, and will soon start clinical trials. SHR-1049 injection is an innovative anti-tumor drug independently developed by the company, intended for the treatment of advanced solid tumors. As of now, there are no similar drugs approved for market both domestically and internationally. Up to now, the accumulated research and development investment in SHR-1049 injection related projects is approximately 26 million yuan (unaudited).